| abstract |
The present invention refers to compounds of the general formula (I) wherein R 1 is hydrogen or hydroxy; R 2 is butyl or butyryl if R 1 is hydroxy, but R 2 is butyl if R 1 is hydrogen; or R 3 and R 2 taken together are 1-propylidene or 1-butylidene optionally substituted by hydroxy, methyl, or 3-(α, β-dimethylacryloyloxy); the dotted line is an optional bond; X is an optionally substituted aliphatic C4-residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3 or X5 if the dotted line in formula (I) is absent; and X is X1, X4 or X5 if the dotted line signifies a bond in formula (I) above; R 3 and R 4 are, independently from each other, hydrogen or hydroxy; and R 5 is hydroxy or butyryl, for use in the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions containing such compounds, and their uses. |